Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
GENFIT Reports Third Quarter 2024 Financial Information
Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30, 2024, including the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen's Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland); November 7, 2024-GENFIT (Nasdaq and Euronext: GNFT), a...
Nasdaq GlobeNewswire
07/11/2024
Global Medical Tapes Market Growth Driven by Aging Population and Healthcare…
The report on the medical tapes segments the market by product type—fabric, paper, plastic—and by application, focusing on wound care, surgery, and other uses. End users are categorized into hospitals and clinics and ambulatory surgical centers. The market is driven by increased healthcare expenditure, technological advances, and the rising prevalence of chronic diseases. It also addresses challenges such as high costs and regulatory complexities while identifying opportunities such as the…
PR Newswire
07/11/2024
A New Era in Medicine: How Antibody Drugs are Revolutionizing Healthcare
This study provides a comprehensive look at the different types of antibody drugs, including human, humanized, chimeric, and murine for the treatment of various diseases. This study provides a comprehensive look at the different types of antibody drugs, including human, humanized, chimeric, and murine for the treatment of various diseases. The report includes market projections, regulatory information, and updates on new products and technologies. It also profiles the leading makers of...
PR Newswire
07/11/2024
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…
Bagsværd, Denmark, 7 November 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk...
Nasdaq GlobeNewswire
07/11/2024
Ipsen - October 2024 - Monthly information relative to the total number of…
Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1)31 October 202483,814,526Gross...
Nasdaq GlobeNewswire
07/11/2024
Safe out of receivership
Safe out of receivershipFleurieux-sur-l'Arbresle-France - November 6, 2024, 6.00 p.m.Safe SA and its subsidiaries announce that they have emerged from the court-ordered receivership proceedings by virtue of a ruling handed down by the Pontoise Commercial Court on Wednesday November 6, 2024, in accordance with the ruling of November 5, 2024. The latter validated the recovery plans as well as the new strategy instilled and implemented by the new management team since...
Nasdaq GlobeNewswire
07/11/2024
Ramsay Sante : Q1 results as of September 30, 2024
PRESS RELEASE PRESS RELEASE Paris, 7 thNovember 2024 Q1 results as of September 30, 2024Unaudited group revenue increased by 8.6% to €1.18bn supported by price increases and volume growth in France and Sweden reflecting sustained patient need for healthcare and the capacity of the group's facilities to provide more care services despite staffing challenges from competition for nurses in Europe. Revenue growth on a like-for-like basis was 5.9%...
Nasdaq GlobeNewswire
07/11/2024
Dragonfly Therapeutics to Present Preclinical Data on Clinical-Stage DF6215, its…
BOSTON, Nov. 7, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing novel immunotherapies, today announced the company will deliver poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Conference, highlighting preclinical data supporting two clinical-stage assets, DF6215, its engineered IL-2 cytokine, and DF9001, its EGFR-targeting TriNKET, for the treatment of advanced solid tumors. BOSTON , Nov. 7, 2024 ...
PR Newswire
07/11/2024
Growth in revenue and operating profit
Trading statement for Q1 2024/25 (1 July - 30 September 2024) Growth in revenue and operating profitRevenue was up 27% in the first quarter of 2024/25 to DKK 115.6 million from DKK 91.1 million in the year-earlier period. The performance reflects growing sales of both instruments, consumables and services. Operating profit (EBITDA) was up 50% in the first quarter to DKK 62.1 million, driven by the revenue growth. The EBITDA margin was 54% for the first quarter. 2024/25 Q1 ...
Nasdaq GlobeNewswire
07/11/2024
Minimal Residual Disease Testing Market Worth $4.45 billion by 2031--Exclusive…
The growth of the minimal residual disease testing market is driven by the growing incidence of cancer, the extensive application of MRD testing in cases of hematological malignancies, the high recurrence rates of some cancers, and increasing investments & funding for MRD testing & research. However, stringent regulatory frameworks and the high costs of MRD testing restrain the growth of this market. The growth of the minimal residual disease testing market is driven by the growing…
PR Newswire
07/11/2024
Global Human Hair Wigs and Extensions Market Poised to Reach USD 9.3 Billion by…
Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=145496 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=145496 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Human Hair Wigs and Extensions Market Overview Geographic Dominance : Geographically,North Americadominates the Human Hair Wigs and Extensions market, withthe United Statesbeing the largest consumer. The region's...
PR Newswire
07/11/2024
Global HLA Typing for Transplant Market to Reach USD 2.1 Billion by 2031, Driven…
Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1014873 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1014873 202 - Pages 126 – Tables 37 – Figures Scope Of The Report HLA Typing For Transplant Market Overview 1. Market Size and Growth Projections The global HLA Typing for Transplant Market is anticipated to grow steadily from 2024 to 2031, with a projected increase fromUSD 1...
PR Newswire
07/11/2024
With CAGR of 8.6%, Poultry Vaccine Market Size to Reach $4.1 Billion By 2031 |…
Read full market research report, "Poultry Vaccines Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Broiler and Layer), Technology (Live Attenuated Vaccines, Inactivated Vaccines, and Recombinant Vaccines), Dosage Form (Liquid Vaccines, Freeze-Dried Vaccines, and Dust/Powder Form Vaccines), Disease [Avian Influenza, Avian Salmonellosis, Marek's Disease, Infectious Bronchitis, Infectious Bursal Disease (IBD)…
PR Newswire
07/11/2024
Periodontal Disease Treatment Market to Hit USD 3.63 Billion by 2030 with 5.9%…
Browse in-depth TOC on "Periodontal Disease Treatment Market" Browse in-depth TOC on "Periodontal Disease Treatment Market" 300 - Tables 60 - Figures320 - Pages In the European region, the legal system involving drugs is the European Medicines Agency (EMA) and devices under the Medical Device Regulation (MDR). The EMA has been careful in ensuring that drugs on periodontal conditions are tested not only for their benefits but also for their risks. In contrast, the MDR has…
PR Newswire
07/11/2024
Women Health App Market Surges to USD 8 Billion by 2030, Propelled by 14.4% CAGR…
Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=216134 Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=216134 Browse in-depth TOC on Women Health App Market 202 - Pages 126 – Tables 37 – Figures Scope of The Report Global Women Health App Market Overview Market Drivers Fueling Growth in the Women Health App Market To Purchase a Comprehensive Report Analysis: ...
PR Newswire
07/11/2024
Next-Generation Sequencing (NGS) Services Market is expected to generate a…
As precision medicine and genomics revolutionize healthcare, the demand for NGS services has surged, driven by advancements in diagnostics, personalized treatment plans, and biopharmaceutical R&D. This report is essential for professionals in life sciences, biotechnology, and clinical research looking to capitalize on the transformative potential of NGS services. As precision medicine and genomics revolutionize healthcare, the demand for NGS services has surged, driven by advancements in...
PR Newswire
07/11/2024
Immunovia presents data from model development study at meeting of the PRECEDE…
The annual meeting of the PRECEDE Consortium will bring together pancreatic cancer experts for two days of informational panels, partner updates, collaboration, and information sharing. Founded in 2020, the international PRECEDE Study is open to individuals with a family history of pancreatic cancer and/or those who carry genetic variants linked to development of the cancer. The PRECEDE Consortium's ambitious goal is to increase the five-year survival rate to 50% within the next 10 years through…
PR Newswire
07/11/2024
The Accumulus Platform Powers Sanofi's Submissions to Multiple Regulators Around…
“The Accumulus platform introduces unprecedented scalability and is designed to unlock the full potential of reliance pathways and regulatory collaboration as a whole,” said Francisco Nogueira, CEO at Accumulus. “We're offering a solution that helps shorten cycle times, accelerate review and feedback, and increase equitable patient access on a global scale. We're not just making reliance pathways viable—we're making them scalable and operational.”Sanofi's adoption of the Accumulus platform...
Nasdaq GlobeNewswire
07/11/2024
Promising cooperation between medac and chiron for the development of organ-on…
Testing new substances in animals is a regulatory cornerstone of drug development. At the same time, the development of animal free testing methods is progressing. In this context the pharmaceutical company medac and the start-up chiron biotechnology are working together on the further development and establishment of animal free testing methods for the pharmaceutical industry. Animal testing still has a role for medical research and the development of therapies. Due to legal requirements...
Nasdaq GlobeNewswire
07/11/2024
Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding…
Additional cancer types were added to the title and content for both guidelines. These updates account for the growing use of genetic testing in cancer prevention, screening, and treatment. Additional cancer types were added to the title and content for both guidelines. These updates account for the growing use of genetic testing in cancer prevention, screening, and treatment. "These expanded guidelines reflect the recommendations from leading experts on genetic testing based on the…
PR Newswire
07/11/2024
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and…
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi's 2024 Global Healthcare Conference in Miami, Florida on December 4, 2024, and in Evercore's HealthCONx Conference in Coral Gables, Florida on December 5, 2024. Members of the management team will host one-on-one meetings at both conferences. Alvotech will also hold a fire-side chat at Evercore's HealthCONx...
Nasdaq GlobeNewswire
07/11/2024
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III…
AV001 is a randomized, double-blind 42-week trial including 410 patients who have been suffering from moderate to severe PSNP for at least six months. The primary endpoint of the trial is a reduction in the average pain intensity after 12 weeks compared to baseline. In addition, the trial assesses other outcomes including reduction in the average pain intensity after 42-weeks, progressive response over time with repeated treatment, reduction of the treatment area over several applications, and…
PR Newswire
07/11/2024
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
Guggenheim's Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MAJefferies London Healthcare Conference on November 19, 2024 presentation at 4:00 p.m. to 4:25 p.m. GDT, in LondonCiti's 2024 Global Healthcare Conference on December 3, 2024 presentation at 9:30 a.m. to 10:10 a.m. ET, in Miami, FLEvercore ISI HealthCONx Conference on December 4, 2024 presentation at 1:20 p.m. to 1:40 p.m. ET, in Coral Gables, FL Live webcasts and archived replays of the...
Nasdaq GlobeNewswire
07/11/2024
Tilray Medical Announces Positive Results from Study on Oral Cannabis Extract…
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)." This randomized, placebo-controlled trial aimed to test the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received capsules containing 2.5 mg of THC and 2.5 mg of CBD or a placebo, taken three times daily for six days.From 2016 to 2022, 147 participants were recruited. The study found that the cannabis extract...
Nasdaq GlobeNewswire
07/11/2024
Altri Comunicati
